Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Around 15% of cases of acute kidney injury (AKI) progress to chronic kidney disease (CKD). Although human placenta-derived mesenchymal stromal cells (hpMSCs) demonstrate anti-inflammatory properties, their long-term effects are unclear. This study aimed to evaluate the preventive effect of hpMSCs on AKI-to-CKD progression and to assess biomarkers sensitivity and correlation.
hpMSCs were isolated, cultured, and characterised by yield, viability, phenotype and immunosuppressive potency. A rat model of ischaemia-reperfusion injury (IRI): both renal pedicles were clamped for 60 minutes. The cells group (IRI-hpMSCs) received 3×10⁵ hpMSCs in each kidney. Control groups received phosphate buffer solution (PBS), IRI only, or no intervention (healthy). Blood (creatinine), urine (KIM-1 and cystatin C) and kidney samples were collected on days 0, 3, 7, 21–28, 56 (n ≥ 3 per timepoint; total n = 57). Serum creatinine was measured in surviving animals. Kidney histology included scoring of acute tubular necrosis (ATN), tubular dilatation (TD), casts, loss of brush border (LBB), and interstitial fibrosis and tubular atrophy (IFTA), with injury quantified by renal injury score (RIS). Calculated correlations. Statistical analysis was performed using SPSS 17.0 and GraphPad Prism 7.04 with non-parametric tests (p < 0.05) and survival curve analysis.
hpMSCs showed consistent viability, expressed MSC markers, and dose-dependently suppressed T-cell proliferation. hpMSCs significantly improved kidney function, with a lower median of serum creatinine levels on day 7 (vs. IRI p = 0.014; vs. PBS p = 0.034). Cystatin C levels were reduced on day 3, and KIM-1 levels were lower on day 14 vs. PBS in the cells group.
Histology revealed that hpMSCs reduced renal injury in both early and late phases. On day 3, the cells group showed significantly less ATN, reduced cast formation, and absence of focal coagulative necrosis by day 7. On days 21–28, RIS, TD, LBB, cast formation, and IFTA were significantly lower in the cells group compared to both controls. IFTA was significantly lower in the cells group on day 56 (vs. IRI, p = 0.018; vs. PBS, p = 0.049).
Serum creatinine normalized on day 28 and 56, but fibrosis persisted only in controls. Despite the limited sample size, several strong correlations were found between early urinary biomarkers and later histological IFTA scores. In the IRI-PBS group, higher KIM-1 (day 14) and cystatin C (day 3) levels were significantly associated with increased IFTA at day 28, but inversely correlated with IFTA at day 56, suggesting possible prolonged kidney damage or delayed regeneration. An increase in cystatin C on day 3 is strongly associated with an increase in IFTA on day 56 in the IRI group, statistically significant. Notably, in the placental cell group, cystatin C elevation (day 3) showed a strong inverse correlation with IFTA at day 28, indicating potential early regenerative effects.
At the end of the study, 100% of the rats in the cells group survived, compared to 68% in the PBS group (p = 0.010) and 72% in the IRI group (p = 0.021).
HPMSCs demonstrate the potential to prevent AKI to CKD and fibrotic progression for up to 56 days. The dynamics of urine and histological biomarkers indicate an increase in chronicity following injury. A 100% survival rate in the cells group supports further preclinical studies on safety and potential clinical translation.
